Xofigo (radium-223 dichloride; Bayer HealthCare Pharmaceuticals Inc.) for treatment of bone metastases in castration-resistant prostate cancer

Record ID 32014000409
Authors' recomendations: Prostate cancer (PC) is the most common cancer in men and the second leading cause of cancer death in men. The annual incidence in the United States is approximately 242,000. Castration-r sistant prostate cancer (CRPC) is defined by rising levels of prostate-specific antigen (PSA) in spite of androgen deprivation therapy and castrate levels of serum testosterone. The overall survival (OS) of men with CRPC is approximately 18 months after treatment with the first-line agent, Taxotere (docetaxel). Late-stage PC commonly metastasizes to the bone, particularly the vertebrae, pelvis, ribs, and skull. Metastases can structurally compromise bones and lead to skeletal-related events (SREs) such as fractures, spinal cord compression, and other neurologic symptoms associated with vertebral fractures, pain, hypercalcemia, decreased quality of life, need for orthopedic surgical intervention, need for analgesics including strong opioids, and pancytopenia related to radiotherapy for SREs. Increases in PSA and markers of bone turnover, such as alkaline phosphatase (ALP), correlate with SREs and OS. Available treatments for bony metastases include external beam radiotherapy (EBRT), bisphosphonates, Prolia (denosumab), and beta-emitting radioisotopes. These may relieve pain or delay SREs, but have not been shown to prolong OS.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Bone Neoplasms
  • Radioisotopes
  • Radium
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.